Azatadina

Azatadina
Estrutura química de Azatadina
Nome IUPAC (sistemática)
11-(1-metilpiperidin-4-ildeno)-6,11-di-hidro-5H-benzo[5,6]ciclohepta[1,2-b]piridina
Identificadores
3964-81-6
19861
DB00719
18709
Informação química
290.402 g/mol
Lista
  • n4c3\C(=C1/CCN(C)CC1)c2ccccc2CCc3ccc
Farmacocinética
Considerações terapêuticas
Aviso médico

Azatadina (nome comercial: Optimina) é um anti-histamínico de primeira geração e anticolinérgico que foi lançado pela Schering-Plough em 1973.

Foi patenteado em 1967. Tem sido sucedido por outros anti-histamínicos e as aprovações de marketing foram amplamente retiradas.

Ver também

Referências

  1. ↑ Katelaris, C. (1990). «Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis». Asian Pacific Journal of Allergy and Immunology. 8 (2): 103–107. PMID 1982614
  2. ↑ Small, P.; Barrett, D.; Biskin, N. (1990). «Effects of azatadine, terfenadine, and astemizole on allergen-induced nasal provocation». Annals of Allergy. 64 (2 Pt 1): 129–131. PMID 1968324
  3. ↑ Azatadine, Villani, F. J.; Caldwell, W. Patente E.U.A. 3 326 924 (1967).
  4. ↑ Horak F. Antialergic and Vasoactive Drugs for Allergic Rhinitis. Chapter 4 in Allergy Frontiers:Therapy and Prevention. Volume 5 of Allergy Frontiers. Eds Pawankar R et al Springer Science & Business Media, 2010 ISBN 9784431993629
  5. ↑ Drugs.com Drugs.com listing for Azatadine Page accessed July 3, 2015
  6. ↑ Federal Register 2005 Food and Drug Administration Docket No.2005N-0058: Hospira, Inc. et al.; Withdrawal of Approval of 76 New Drug Applications and 60 Abbreviated New Drug Applications 70 FR 10651
  7. ↑ Federal Register 2007 Food and Drug Administration Docket No. 2004P-0262: Withdrawal of Approval of 128 Suitability Petitions 72 FR 8184
  8. ↑ Department of Economic and Social Affairs of the United Nations Secretariat Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments Twelfth Issue: Pharmaceuticals United Nations – New York, 2005
  9. ↑ FDA OGD Suitability Tracking Report (Sorted by Drug Name) Page accessed July 3, 2015